RA
ADAP

RFG Advisory’s Adaptimmune Therapeutics ADAP Stock Holding History

RFG Advisory’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,000
Closed -$21K – 613
2022
Q3 		$21K Buy
+10,000
New +$18.4K ﹤0.01% 611

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

RFG Advisory's ADAP Position: Q4 2022 in Review

RFG Advisory sold out of Adaptimmune Therapeutics (ADAP) in Q4 2022, closing a stake of 10,000 shares — an estimated $21K sold.

RFG Advisory first reported a position in ADAP in Q3 2022 and held it in 1 quarter. The position peaked at $21K in Q3 2022. 69 funds tracked by Wall St. Rank hold ADAP as of Q4 2022.

  • RFG Advisory reported no remaining Adaptimmune Therapeutics position as of Q4 2022 after selling out during the quarter.
  • RFG Advisory sold 10,000 Adaptimmune Therapeutics shares in Q4 2022, an estimated $21K.
  • RFG Advisory first reported a position in Adaptimmune Therapeutics in Q3 2022 and held it in 1 quarter.
  • RFG Advisory's Adaptimmune Therapeutics position peaked at $21K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2022.

Based on RFG Advisory's 13F filing for Q4 2022, filed 15 Feb 2023.